Olema Pharmaceuticals, Inc. (OLMA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
OLMA currently has 87.3M outstanding shares. with significant dilution risk as 121M authorized shares could dilute existing holders by 138.7%. The company has significantly diluted shareholders by 48.66% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 87.3M shares outstanding |
87M | 120M |
| Mar 16, 2026 |
10-K filing | 87.0M shares outstanding |
87M | 120M |
| Nov 10, 2025 |
10-Q filing | 68.7M shares outstanding |
69M | 120M |
| May 13, 2025 |
10-Q filing | 68.4M shares outstanding |
68M | 120M |
| Mar 18, 2025 |
10-K filing | 68.3M shares outstanding |
68M | 120M |
| Jan 06, 2025 |
S-3 filing: Olema Pharmaceuticals, Inc. may offer and sell up to an aggregate amount of $200,000,000 of any combination of common stock, preferred stock, or debt securities. |
57M | 120M |
| Jan 03, 2025 |
S-3 filing: This prospectus relates to the resale by the selling stockholders of up to 27,533,038 shares of common stock, consisting of shares and shares issuable upon the exercise of outstanding pre-funded warrants. |
57M | 96M |
| Dec 02, 2024 |
8-K filing: Olema Pharmaceuticals, Inc. entered into a securities purchase agreement for a private placement of 19,928,875 shares of common stock at $9.08 per share and pre-funded warrants to purchase up to 7,604,163 shares of common stock at $9.0799 per share, with gross proceeds of approximately $250.0 million expected to close on or about December 4, 2024. ($250.0M proceeds) |
57M | 68M |
| Nov 12, 2024 |
10-Q filing | 57.3M shares outstanding |
57M | 68M |
| Aug 06, 2024 |
10-Q filing | 56.3M shares outstanding |
56M | 68M |
| May 08, 2024 |
10-Q filing | 55.6M shares outstanding |
56M | 68M |
| Mar 11, 2024 |
10-K filing | 55.9M shares outstanding |
56M | 68M |
| Jan 31, 2024 |
S-3 filing: This prospectus relates to the resale from time to time of up to 13,211,381 shares of our common stock held by the selling stockholders identified in this prospectus, which were issued by us in a private placement on September 12, 2023. |
55M | 68M |
| Nov 07, 2023 |
10-Q filing | 54.8M shares outstanding |
55M | 55M |
| Aug 08, 2023 |
10-Q filing | 40.7M shares outstanding |
41M | 55M |
| May 09, 2023 |
10-Q filing | 40.4M shares outstanding |
40M | 55M |
| Mar 09, 2023 |
10-K filing | 40.0M shares outstanding |
40M | 55M |
| Nov 08, 2022 |
10-Q filing | 40.0M shares outstanding |
40M | 55M |
| Aug 09, 2022 |
10-Q filing | 39.9M shares outstanding |
40M | 55M |
| May 09, 2022 |
10-Q filing | 39.8M shares outstanding |
40M | 55M |
| Mar 01, 2022 |
S-3 filing: Olema Pharmaceutical Inc. files an S-3 to offer and sell up to an aggregate amount of $200,000,000 of any combination of common stock, preferred stock and debt securities. |
40M | 55M |
| Feb 28, 2022 |
10-K filing | 39.5M shares outstanding |
40M | 12M |
| Nov 10, 2021 |
10-Q filing | 39.6M shares outstanding |
40M | 12M |
| Aug 10, 2021 |
10-Q filing | 39.4M shares outstanding |
39M | 12M |
| May 11, 2021 |
10-Q filing | 40.2M shares outstanding |
40M | 12M |
| Nov 16, 2020 |
S-1/A filing: Olema Pharmaceuticals, Inc. is offering 10,000,000 shares of common stock in an initial public offering, with an expected price between $16.00 and $18.00 per share. The underwriters have an option to purchase up to 1,500,000 additional shares. |
N/A | 12M |
| Oct 30, 2020 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock by Olema Pharmaceuticals, Inc. |
N/A | 0 |